30 days ago
Accenture (ACN) stock trades near $195, and the options market prices roughly a two-in-three chance that it ends the coming twelve months between about $123 and about $308. That floor is about where the stock bottomed over the past year, and the ceiling is above the high it has already given back. For a holder, the question is whether a band that wide is more than you signed up for.
How Much Of Your Position Is On The Table Each Way?
The floor sits about 37% below today's price, a fall of $71.59, and the ceiling about 58% above it, a rise of $113.12. The bigger upside figure is not a lean: a share price can rise without limit and cannot fall below zero, so the band is always wider in dollars on the way up.
Has Accenture Stock Moved This Much Before?
It has. The stock traded between $122.96 and $282.71 over the past 52 weeks, and it lost 17.5% over the trailing twelve months while the S&P 500 gained 17%. Realized volatility over that year was 44.9%, and the one-year options carry implied volatility of 45.5%, a ratio of 1.01. The chain is pricing another year of movement about the size of the last one.
#twelve #floor
How Much Of Your Position Is On The Table Each Way?
The floor sits about 37% below today's price, a fall of $71.59, and the ceiling about 58% above it, a rise of $113.12. The bigger upside figure is not a lean: a share price can rise without limit and cannot fall below zero, so the band is always wider in dollars on the way up.
Has Accenture Stock Moved This Much Before?
It has. The stock traded between $122.96 and $282.71 over the past 52 weeks, and it lost 17.5% over the trailing twelve months while the S&P 500 gained 17%. Realized volatility over that year was 44.9%, and the one-year options carry implied volatility of 45.5%, a ratio of 1.01. The chain is pricing another year of movement about the size of the last one.
#twelve #floor
1 month ago
Danaos Corporation (DAC) is a leading global containership owner.
DAC exhibits robust technical momentum with shares trading at a new all-time high.
The stock is up nearly 70% over the past year.
Danaos also pays a dividend that yields 2.27%.
Valued at $2.86 billion, Danaos (DAC) is a leading international owner of containerships, chartering vessels to many of the world's largest liner companies.
#owner #valued #global
DAC exhibits robust technical momentum with shares trading at a new all-time high.
The stock is up nearly 70% over the past year.
Danaos also pays a dividend that yields 2.27%.
Valued at $2.86 billion, Danaos (DAC) is a leading international owner of containerships, chartering vessels to many of the world's largest liner companies.
#owner #valued #global
1 month ago
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Republicans are well known for opposing tax increases and since 1986, many Republican officeholders have signed on to the Taxpayer Protection Pledge (1).
Rolled out with former President Ronald Reagan's endorsement, the pledge is a commitment in writing to oppose "any and all" tax increases. Currently, 44 members of the Senate and 194 representatives in Congress have signed the pledge.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
A record 45% of central banks plan to grow gold reserves — and many investors are following suit. Get your free gold IRA guide from Priority Gold
#republicans #republican
Republicans are well known for opposing tax increases and since 1986, many Republican officeholders have signed on to the Taxpayer Protection Pledge (1).
Rolled out with former President Ronald Reagan's endorsement, the pledge is a commitment in writing to oppose "any and all" tax increases. Currently, 44 members of the Senate and 194 representatives in Congress have signed the pledge.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
A record 45% of central banks plan to grow gold reserves — and many investors are following suit. Get your free gold IRA guide from Priority Gold
#republicans #republican
1 month ago
On Valentine's day, Illinois resident Brenda Daurham was thankful she had home insurance when a pipe under her sink burst, causing serious water damage throughout her property.
Over six months later, Daurham is still displaced from her home after Allstate refused to pay for the repairs.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#illinois
Over six months later, Daurham is still displaced from her home after Allstate refused to pay for the repairs.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes
#illinois
1 month ago
On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven's lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven's Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines up with an August 10, 2026 earnings report that showed Biohaven still losing well over $100 million a quarter, and the gap between those two dates explains a lot about why this deal happened now.
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.
#ro
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.
#ro
1 month ago
Just when everyone thought that Nvidia (NVDA) may have lost its magic, it has pulled a rabbit out of the hat. No, it is not the usual beat and raise from its quarterly results. This time, Nvidia did something it has never done before—guiding for the next fiscal year. This was a major contributing factor to its shares not falling following its earnings, a phenomenon of the last four consecutive quarters.
In fact, the stock was up by as much as 10% at its highest point in the two subsequent trading sessions. Overall, the stock is up about 5% since the earnings.
Dear Sandisk Stock Fans, Mark Your Calendars for August 31
Dear Palantir Stock Fans, Here's What Maven's Billion-Dollar ARR Means for PLTR
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
#NVIDIA #dear #earnings #overall
In fact, the stock was up by as much as 10% at its highest point in the two subsequent trading sessions. Overall, the stock is up about 5% since the earnings.
Dear Sandisk Stock Fans, Mark Your Calendars for August 31
Dear Palantir Stock Fans, Here's What Maven's Billion-Dollar ARR Means for PLTR
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
#NVIDIA #dear #earnings #overall
2 months ago
Millennials face a retirement savings paradox: the harder they try to stay disciplined, the more headwinds seem to appear. Housing costs are surging. Job security is evaporating. And unexpected expenses keep materializing right when that $500 monthly retirement contribution finally fits into the budget.
The problem isn't willpower. It's that the financial landscape is actively working against them. Here are four major factors quietly sabotaging retirement plans and what to actually do about them.
Two decades ago, income growth and rental increases were roughly in sync. Not anymore. According to the Joint Center for Housing Studies at Harvard, rent has skyrocketed while renter incomes have barely budged. The result is rent eating an increasingly larger chunk of your paycheck, which means less money flowing into retirement accounts.
To help combat this, brush off your negotiating skills when it's time to renew your rent. Most landlords value a reliable tenant who pays on time over squeezing out another $50 per month. If that doesn't work, consider splitting housing costs with a roommate.
According to the Federal Reserve, 37% of adults can't cover a $400 surprise expense without borrowing. A busted transmission, an ER visit, a sudden job loss — any of these can torpedo your financial plan if you're not prepared. Without an emergency cushion, you'll have lean on your credit card. Then you're paying interest on debt instead of building retirement wealth.
#millennials
The problem isn't willpower. It's that the financial landscape is actively working against them. Here are four major factors quietly sabotaging retirement plans and what to actually do about them.
Two decades ago, income growth and rental increases were roughly in sync. Not anymore. According to the Joint Center for Housing Studies at Harvard, rent has skyrocketed while renter incomes have barely budged. The result is rent eating an increasingly larger chunk of your paycheck, which means less money flowing into retirement accounts.
To help combat this, brush off your negotiating skills when it's time to renew your rent. Most landlords value a reliable tenant who pays on time over squeezing out another $50 per month. If that doesn't work, consider splitting housing costs with a roommate.
According to the Federal Reserve, 37% of adults can't cover a $400 surprise expense without borrowing. A busted transmission, an ER visit, a sudden job loss — any of these can torpedo your financial plan if you're not prepared. Without an emergency cushion, you'll have lean on your credit card. Then you're paying interest on debt instead of building retirement wealth.
#millennials
